Trial · NCT01868360
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
NCT01868360, Phase 1, Terminated, Balamurali Ambati
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea. Trials, record NCT01868360. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01868360
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
- NCT number
- NCT01868360
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 2 participants, actual
- Lead sponsor
- Balamurali Ambati
- Conditions
- Corneal Neovascularization
- Interventions
- Subconjunctival aflibercept, Placebo: Standard of care only
- First posted
- 2013-06-04
- Last updated
- 2015-10-07
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety defined by incidence and severity of adverse events at week 28 | Week 28 | The primary endpoint in the study is safety as defined by incidence and severity of adverse events in patients with corneal neovascularization undergoing corneal transplant. |
| Secondary | neovascularization regression | at time of transplant | Ability of subconjunctival aflibercept injection to regress neovascularization at time of transplant and promote graft survival after corneal transplantation |
| Secondary | Need for immunosuppression | Week 28 | Need for immunosuppression at week 28 in both treatment groups |
| Secondary | Effect on corneal infections | Through week 28 | Effect on corneal infections or other side effects through week 28 in both treatment groups |
| Secondary | Change in visual acuity | Week 28 | Change in ETDRS visual acuity from baseline at week 28 in both treatment groups |
| Secondary | Mean number of injections | Week 28 | Mean number of injections performed per patient through week 28 in patients receiving subconjunctival aflibercept injections |
| Secondary | Rescue therapy | Week 28 | Need for rescue treatment in the standard of care group through week 28 |
| Secondary | neovascularization regression | at 28 weeks after transplant | Ability of subconjunctival aflibercept injection to regress neovascularization (at 28 weeks after transplant) and promote graft survival after corneal transplantation |
| Secondary | neovascularization regression | at 52 weeks after transplantation | Ability of subconjunctival aflibercept injection to regress neovascularization at 52 weeks after transplant and promote graft survival after corneal transplantation |
| Secondary | Need for immunosuppression | week 52 | need for immunosuppression at week 52 in both treatment groups |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01868360
GET https://conductscience.org/api/trials/v1/NCT01868360/registered